BREAKING NEWS

Merck's COVID-19 pill effective against Omicron in lab studies

Merck and partner Ridgeback Biotherapeutics said on Friday six lab studies showed that their experimental oral COVID-19 drug, molnupiravir, was active against the Omicron variant.

Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use and privacy policy